Climate Change Data

OKYO Pharma Limited

Climate Impact & Sustainability Data (2020, 2022)

Reporting Period: 2020

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Social Achievements

  • Low staff turnover.

Governance Achievements

  • Implemented a corporate governance structure.
  • Established three committees: Audit, Risk and Disclosure, and Nomination.

Climate Goals & Targets

Short-term Goals:
  • Develop appropriate formulation of Chemerin (OKYO-101) for animal studies and conduct stability studies to ensure that the formulation is stable for at least 28 days.

Environmental Challenges

  • Clinical studies may not generate encouraging data.
  • Ability to scale up the Group's growth.
  • Intellectual property risk.
  • Competition risk.
  • Funding risk.
  • Dependence on key personnel.
  • Environmental liability inherent in outsourced activities.
  • Stringent environmental, health, and safety regulations.
Mitigation Strategies
  • Tight financial control, prioritizing programs for best returns, keeping shareholders informed.
  • Recruiting additional personnel and incentivizing them through equity incentive schemes.
  • Outsourcing research, development, testing, and manufacturing activities to mitigate environmental risks.
  • Monitoring regulatory developments and addressing issues in decision-making.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • New supplier agreements above a material threshold need to be approved by at least two Directors.

Climate-Related Risks & Opportunities

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Not disclosed

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • File an IND on OK-101 to treat DED in Q4 2022.
  • Commence Phase 2 trial of OK-101 in Q1 2023.

Environmental Challenges

  • Net losses and significant cash outflows from operating activities.
  • Accumulated deficit of £76.8m.
  • Material uncertainty about the Group’s ability to continue as a going concern due to insufficient cash to meet liabilities.
  • Projected cash exhaustion by October 2022 without additional financing.
Mitigation Strategies
  • Dual listing on NASDAQ to access US liquidity.
  • Development of OK101 clinical program with near-term inflection points for financing opportunities (IND approval, Phase II data).
  • Secured a $2m short-term credit facility with a related party to bridge delays and extend cash burn to April 2023.
  • Additional working capital management measures.
  • Planning alternative financing strategies with investment bankers.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed